Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome - where do we go from here?

Critical Care

Volumn 16, Issue 6, 2012, Pages

  Dushianthan, Ahilanandan ^a,b   Cusack, Rebecca ^a   Goss, Victoria ^b   Postle, Anthony D ^b   Grocott, Mike P W ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT; PHOSPHOLIPID; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; CONCENTRATION (PARAMETERS); ELECTROSPRAY MASS SPECTROMETRY; LUNG GAS EXCHANGE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; OXIDATION; OXYGENATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SURVIVAL; ADULT; HUMAN; RESPIRATORY DISTRESS SYNDROME, ADULT;

ACUTE LUNG INJURY; ADULT; HUMANS; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84869883778     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11512     Document Type: Review

References (67)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967, 2:319-323.
2. Villar J, Blanco J, Añón JM, Santos-Bouza A, Blanch L, Ambrós A, Gandía F, Carriedo D, Mosteiro F, Basaldúa S, Fernández RL, Kacmarek RM, . ALIEN Network The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med 2011, 37:1932-1941. 10.1007/s00134-011-2380-4, 21997128, ALIEN Network.
3. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000, 342:1334-1349. 10.1056/NEJM200005043421806, 10793167.
4. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149:818-824.
5. Ferguson ND, Frutos-Vivar F, Esteban A, Fernandez-Segoviano P, Aramburu JA, Najera L, Stewart TE. Acute respiratory distress syndrome: underrecognition by clinicians and diagnostic accuracy of three clinical definitions. Crit Care Med 2005, 33:2228-2234. 10.1097/01.CCM.0000181529.08630.49, 16215375.
6. Rubenfeld GD, Caldwell E, Granton J, Hudson LD, Matthay MA. Interobserver variability in applying a radiographic definition for ARDS. Chest 1999, 116:1347-1353. 10.1378/chest.116.5.1347, 10559098.
7. Soni N. ARDS, acronyms and the Pinocchio effect. Anaesthesia 2010, 65:976-979. 10.1111/j.1365-2044.2010.06508.x, 21198467.
8. Ranieri V, Rubenfeld GD, Thompson B, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS, Antonelli M, Anzueto A, Beale R, Brochard L, Brower R, Esteban A, Gattinoni L, Rhodes A, Vincent JL, Bersten A, Needham D, Pesenti A. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012, 307:2526-2533.
9. Rooney SA, Young SL, Mendelson CR. Molecular and cellular processing of lung surfactant. FASEB J 1994, 8:957-967.
10. Lang CJ, Postle AD, Orgeig S, Possmayer F, Bernhard W, Panda AK, Jurgens KD, Milsom WK, Nag K, Daniels CB. Dipalmitoylphosphatidylcholine is not the major surfactant phospholipid species in all mammals. Am J Physiol Regul Integr Comp Physiol 2005, 289:R1426-R1439. 10.1152/ajpregu.00496.2004, 16037124.
11. Schmidt R, Markart P, Ruppert C, Wygrecka M, Kuchenbuch T, Walmrath D, Seeger W, Guenther A. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007, 8:55. 10.1186/1465-9921-8-55, 1950506, 17662121.
12. Postle AD, Heeley EL, Wilton DC. A comparison of the molecular species compositions of mammalian lung surfactant phospholipids. Comp Biochem Physiol A Mol Integr Physiol 2001, 129:65-73. 10.1016/S1095-6433(01)00306-3, 11369534.
13. Haagsman HP, Diemel RV. Surfactant-associated proteins: functions and structural variation. Comp Biochem Physiol A Mol Integr Physiol 2001, 129:91-108. 10.1016/S1095-6433(01)00308-7, 11369536.
14. Petty TL, Silvers GW, Paul GW, Stanford RE. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. Chest 1979, 75:571-574. 10.1378/chest.75.5.571, 582029.
15. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982, 70:673-683. 10.1172/JCI110662, 370271, 6896715.
16. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA, Hudson LD, Maunder RJ, Crim C, Hyers TM. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991, 88:1976-1981. 10.1172/JCI115523, 295781, 1752956.
17. Gunther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996, 153:176-184.
18. Nakos G, Kitsiouli EI, Tsangaris I, Lekka ME. Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components. Intensive Care Med 1998, 24:296-303. 10.1007/s001340050571, 9609406.
19. Pison U, Seeger W, Buchhorn R, Joka T, Brand M, Obertacke U, Neuhof H, Schmit-Neuerburg KP. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989, 140:1033-1039.
20. Schmidt R, Meier U, Yabut-Perez M, Walmrath D, Grimminger F, Seeger W, Gunther A. Alteration of fatty acid profiles in different pulmonary surfactant phospholipids in acute respiratory distress syndrome and severe pneumonia. Am J Respir Crit Care Med 2001, 163:95-100.
21. Mason RJ, Nellenbogen J, Clements JA. Isolation of disaturated phosphatidylcholine with osmium tetroxide. J Lipid Res 1976, 17:281-284.
22. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am J Respir Crit Care Med 1999, 160:1843-1850.
23. Veldhuizen RA, Inchley K, Hearn SA, Lewis JF, Possmayer F. Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates. Biochem J 1993, 295:141-147. 1134830, 8216208.
24. Holm BA, Matalon S, Finkelstein JN, Notter RH. Type II pneumocyte changes during hyperoxic lung injury and recovery. J Appl Physiol 1988, 65:2672-2678.
25. Lewis JF, Ikegami M, Jobe AH. Altered surfactant function and metabolism in rabbits with acute lung injury. J Appl Physiol 1990, 69:2303-2310.
26. Postle AD, Hunt AN. Dynamic lipidomics with stable isotope labelling. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:2716-2721. 10.1016/j.jchromb.2009.03.046, 19395321.
27. Simonato M, Baritussio A, Ori C, Vedovelli L, Rossi S, Dalla ML, Rizzi S, Carnielli VP, Cogo PE. Disaturated-phosphatidylcholine and surfactant protein-B turnover in human acute lung injury and in control patients. Respir Res 2011, 12:36. 10.1186/1465-9921-12-36, 3072954, 21429235.
28. Ware LB, Koyama T, Billheimer DD, Wu W, Bernard GR, Thompson BT, Brower RG, Standiford TJ, Martin TR, Matthay MA, . NHLBI ARDS Clinical Trials Network Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010, 137:288-296. 10.1378/chest.09-1484, 2816641, 19858233, NHLBI ARDS Clinical Trials Network.
29. Holm BA, Wang Z, Notter RH. Multiple mechanisms of lung surfactant inhibition. Pediatr Res 1999, 46:85-93. 10.1203/00006450-199907000-00015, 10400140.
30. Gunasekara L, Schoel WM, Schurch S, Amrein MW. A comparative study of mechanisms of surfactant inhibition. Biochim Biophys Acta 2008, 1778:433-444. 10.1016/j.bbamem.2007.10.027, 18036553.
31. Haagsman HP. Oxidative damage of the pulmonary surfactant system. Semin Neonatol 1998, 3:207-217.
32. Rodriguez-Capote K, Manzanares D, Haines T, Possmayer F. Reactive oxygen species inactivation of surfactant involves structural and functional alterations to surfactant proteins SP-B and SP-C. Biophys J 2006, 90:2808-2821. 10.1529/biophysj.105.073106, 1414557, 16443649.
33. Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, Bonventre JV. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Physiol 1995, 269:L109-L118.
34. Cockshutt AM, Possmayer F. Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins. Biochim Biophys Acta 1991, 1086:63-71. 10.1016/0005-2760(91)90155-B, 1954245.
35. Hite RD, Seeds MC, Jacinto RB, Grier BL, Waite BM, Bass DA. Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis. Biochim Biophys Acta 2005, 1720:14-21. 10.1016/j.bbamem.2005.10.014, 16376294.
36. Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME. Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005, 33:772-779. 10.1097/01.CCM.0000158519.80090.74, 15818104.
37. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1980, 1:55-59.
38. Halliday HL. Surfactants: past, present and future. J Perinatol 2008, 28(Suppl 1):S47-S56.
39. Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, Horton J, Pattishall EN. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994, 272:1433-1438. 10.1001/jama.1994.03520180057035, 7933425.
40. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996, 334:1417-1421. 10.1056/NEJM199605303342201, 8618579.
41. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, Hudson LD, Crim C, Newton P, Mitchell BR, Gold AJ. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997, 155:1309-1315.
42. Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby JJ, Holzapfel L, Bruins P, Steenken EJ, Jeppesen OK, Lachmann B. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009, 180:989-994. 10.1164/rccm.200812-1955OC, 19713451.
43. Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD, Marsh JJ. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003, 167:1562-1566. 10.1164/rccm.200207-782OC, 12649125.
44. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, Häfner D, Taut FJ, Seeger W. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004, 351:884-892. 10.1056/NEJMoa033181, 15329426.
45. Markart P, Reppert C, Wygrecka M, Coaris T, Dahal B, Walmrath D, Harbach H, Wilhelm J, Seeger W, Schmidt R, Guenther A. Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Thorax 2007, 62:588-594. 10.1136/thx.2006.062398, 2117258, 17287298.
46. Spragg RG, Taut FJ, Lewis JF, Schenk P, Ruppert C, Dean N, Krell K, Karabinis A, Gunther A. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med 2011, 183:1055-1061. 10.1164/rccm.201009-1424OC, 21148720.
47. Meng H, Sun Y, Lu J, Fu S, Meng Z, Scott M, Li Q. Exogenous surfactant may improve oxygenation but not mortality in adult patients with acute lung injury/acute respiratory distress syndrome: a meta-analysis of 9 clinical trials. J Cardiothorac Vasc Anesth 2012, 26:849-856. 10.1053/j.jvca.2011.11.006, 22265270.
48. Lewis J, McCaig L, Hafner D, Spragg R, Veldhuizen R, Kerr C. Dosing and delivery of a recombinant surfactant in lung-injured adult sheep. Am J Respir Crit Care Med 1999, 159:741-747.
49. Spragg RG, Gilliard N, Richman P, Smith RM, Hite RD, Pappert D, Robertson B, Curstedt T, Strayer D. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994, 105:195-202. 10.1378/chest.105.1.195, 8031347.
50. Walmrath D, Grimminger F, Pappert D, Knothe C, Obertacke U, Benzing A, Gunther A, Schmehl T, Leuchte H, Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur Respir J 2002, 19:805-810. 10.1183/09031936.02.00243402, 12030717.
51. Gunther A, Schmidt R, Harodt J, Schmehl T, Walmrath D, Ruppert C, Grimminger F, Seeger W. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties. Eur Respir J 2002, 19:797-804. 10.1183/09031936.02.00243302, 12030716.
52. Schurch S, Possmayer F, Cheng S, Cockshutt AM. Pulmonary SP-A enhances adsorption and appears to induce surface sorting of lipid extract surfactant. Am J Physiol 1992, 263:L210-L218.
53. Higuchi R, Lewis J, Ikegami M. In vitro conversion of surfactant subtypes is altered in alveolar surfactant isolated from injured lungs. Am Rev Respir Dis 1992, 145:1416-1420.
54. Soll RF. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000, 2:CD000144.
55. Diemel RV, Walch M, Haagsman HP, Putz G. In vitro and in vivo intrapulmonary distribution of fluorescently labeled surfactant. Crit Care Med 2002, 30:1083-1090. 10.1097/00003246-200205000-00020, 12006806.
56. Gattinoni L, Chiumello D, Cressoni M, Valenza F. Pulmonary computed tomography and adult respiratory distress syndrome. Swiss Med Wkly 2005, 135:169-174.
57. Cockshutt AM, Weitz J, Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990, 29:8424-8429. 10.1021/bi00488a032, 2252903.
58. Seeger W, Gunther A, Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am J Physiol 1992, 262:L286-L291.
59. Notter RH, Schwan AL, Wang Z, Waring AJ. Novel phospholipase-resistant lipid/peptide synthetic lung surfactants. Mini Rev Med Chem 2007, 7:932-944. 10.2174/138955707781662627, 17897082.
60. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, Longacre S, Vargaftig BB, Béréziat G, Voelker DR, Wolf C, Touqui L. Generation of lysophospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein Aphospholipase A2 protein interaction. J Clin Invest 1998, 102:1152-1160. 10.1172/JCI3236, 509098, 9739049.
61. Seeger W, Lepper H, Wolf HR, Neuhof H. Alteration of alveolar surfactant function after exposure to oxidative stress and to oxygenated and native arachidonic acid in vitro. Biochim Biophys Acta 1985, 835:58-67. 10.1016/0005-2760(85)90030-X, 3924109.
62. Gilliard N, Heldt GP, Loredo J, Gasser H, Redl H, Merritt TA, Spragg RG. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties. J Clin Invest 1994, 93:2608-2615. 10.1172/JCI117273, 294496, 8200999.
63. Domingues MR, Reis A, Domingues P. Mass spectrometry analysis of oxidized phospholipids. Chem Phys Lipids 2008, 156:1-12. 10.1016/j.chemphyslip.2008.07.003, 18671956.
64. Bridges JP, Davis HW, Damodarasamy M, Kuroki Y, Howles G, Hui DY, McCormack FX. Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury. J Biol Chem 2000, 275:38848-38855.
65. Bouhafs RK, Jarstrand C. Effects of antioxidants on surfactant peroxidation by stimulated human polymorphonuclear leukocytes. Free Radic Res 2002, 36:727-734. 10.1080/10715760290032593, 12180122.
66. Carnielli VP, Zimmermann LJ, Hamvas A, Cogo PE. Pulmonary surfactant kinetics of the newborn infant: novel insights from studies with stable isotopes. J Perinatol 2009, 29(Suppl 2):S29-S37.
67. Bernhard W, Pynn CJ, Jaworski A, Rau GA, Hohlfeld JM, Freihorst J, Poets CF, Stoll D, Postle AD. Mass spectrometric analysis of surfactant metabolism in human volunteers using deuteriated choline. Am J Respir Crit Care Med 2004, 170:54-58. 10.1164/rccm.200401-089OC, 15044202.